Rovati
CEO and CSO
Business management
Olatec
Denmark
Biography
In September 2015, Lucio C. Rovati, MD, joined Olatec’s Scientific Advisory Board. For Olatec, Dr. Rovati brings extensive experience in drug development and clinical programs, particularly in osteoarthritis. Dr. Rovati is CEO and CSO of Rottapharm Biotech S.r.l., the R&D spin-off of the former Rottapharm pharmaceutical company. Rottapharm Biotech is a company of biotechnologies committed to the discovery, research and development of new innovative therapeutic drugs, both chemical and biological in nature.
Research Interest
Dr. Rovati is responsible for all scientific and R&D activities of the company, with direct reporting from all operative functions, including: medicinal chemistry, antibody discovery & protein engineering, pharmacology and toxicology, translational sciences and pharmacokinetics, pharmaceutical technology, biostatistics, clinical research, regulatory and quality, business development, scientific liaison and drug safety.
